CKF Coalitions Propel Policy and Procedural Changes

Examines how grantees of RWJF's project to increase enrollment in Medicaid and State Children's Health Insurance Programs formed coalitions of community groups, government agencies, and others; what types of policy change they achieved; and for how long

Improving Public Coverage for Children: Lessons From CKF in New Jersey

Reviews how grantees of RWJF's initiative to boost enrollment in Medicaid and the State Children's Health Insurance Program worked closely with state officials to support outreach efforts, with a sustained positive impact. Looks at recent coverage trends

Covering Kids & Families Evaluation: Synthesis of 10 Case Studies: Exploring Medicaid and SCHIP Enrollment Trends and Their Links to Policy and Practice

Highlights thematic findings from case studies in ten states of RWJF's 1999-2006 initiative to increase enrollment in Medicaid and State Children's Health Insurance Programs through outreach, simplified procedures, and collaboration with state agencies

Consumer Voices for Coverage: Advocacy Evaluation Toolkit

Offers step-by-step guidance on evaluating advocacy projects, including developing a logic model, collecting evaluation data, and using focus groups and interviews to evaluate or inform program performance. Includes surveys on RWJF's advocacy initiative

Building Advocacy Capacity: Where Grantees Started

Describes the baseline levels of core advocacy capacities of groups participating in Consumer Voices for Coverage, a twelve-state initiative to build consumer organizations' network and advocacy capacity. Discusses lessons learned and recommendations

Covering Kids & Families Evaluation: Strategies for Sustaining CKF: Interim Synthesis of Evaluation Findings

Explores state grantees' and coalitions' views on the sustainability of their efforts to help eligible families enroll in public health insurance after RWJF funding ends, the permanence of the changes effected, and their implications for CKF activities

Covering Kids & Families: A Continuing Program for Increasing Insurance Coverage Among Low-Income Families

Explores the impact of the program's coalition-based approaches to improving Children's Health Insurance and Medicaid programs to increase enrollment on policy and procedures and assesses the outcomes of policy change on coverage of children and parents

International Nonregimes: A Research Agenda1

Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/146934/1/j.1468-2486.2007.00672.x.pd

Adjunctive rifampicin for Staphylococcus aureus bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial.

BACKGROUND: Staphylococcus aureus bacteraemia is a common cause of severe community-acquired and hospital-acquired infection worldwide. We tested the hypothesis that adjunctive rifampicin would reduce bacteriologically confirmed treatment failure or disease recurrence, or death, by enhancing early S aureus killing, sterilising infected foci and blood faster, and reducing risks of dissemination and metastatic infection. METHODS: In this multicentre, randomised, double-blind, placebo-controlled trial, adults (≥18 years) with S aureus bacteraemia who had received ≤96 h of active antibiotic therapy were recruited from 29 UK hospitals. Patients were randomly assigned (1:1) via a computer-generated sequential randomisation list to receive 2 weeks of adjunctive rifampicin (600 mg or 900 mg per day according to weight, oral or intravenous) versus identical placebo, together with standard antibiotic therapy. Randomisation was stratified by centre. Patients, investigators, and those caring for the patients were masked to group allocation. The primary outcome was time to bacteriologically confirmed treatment failure or disease recurrence, or death (all-cause), from randomisation to 12 weeks, adjudicated by an independent review committee masked to the treatment. Analysis was intention to treat. This trial was registered, number ISRCTN37666216, and is closed to new participants. FINDINGS: Between Dec 10, 2012, and Oct 25, 2016, 758 eligible participants were randomly assigned: 370 to rifampicin and 388 to placebo. 485 (64%) participants had community-acquired S aureus infections, and 132 (17%) had nosocomial S aureus infections. 47 (6%) had meticillin-resistant infections. 301 (40%) participants had an initial deep infection focus. Standard antibiotics were given for 29 (IQR 18-45) days; 619 (82%) participants received flucloxacillin. By week 12, 62 (17%) of participants who received rifampicin versus 71 (18%) who received placebo experienced treatment failure or disease recurrence, or died (absolute risk difference -1·4%, 95% CI -7·0 to 4·3; hazard ratio 0·96, 0·68-1·35, p=0·81). From randomisation to 12 weeks, no evidence of differences in serious (p=0·17) or grade 3-4 (p=0·36) adverse events were observed; however, 63 (17%) participants in the rifampicin group versus 39 (10%) in the placebo group had antibiotic or trial drug-modifying adverse events (p=0·004), and 24 (6%) versus six (2%) had drug interactions (p=0·0005). INTERPRETATION: Adjunctive rifampicin provided no overall benefit over standard antibiotic therapy in adults with S aureus bacteraemia. FUNDING: UK National Institute for Health Research Health Technology Assessment